The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

<div>Evolution of mean Hb concentration during the two phases of the study. Hb: hemoglobin, EpoB recombinant human erythropoietin beta, CERA: continuous erythropoietin receptor activator, and CSR: clinical success rate (HB within the target 10,5–12 g/dL).</div>

Anemia

fig2

Figure 2

Figure 2: The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients 

Figure 2 | The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients 